Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV)

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.

GSK plc（倫敦證券交易所/紐約證券交易所代碼：GSK）今天宣布，美國食品藥品監督管理局（FDA）已批准 Arexvy（呼吸道合胞病毒疫苗，佐劑）用於預防由呼吸道合胞病毒（RSV）引起的下呼吸道疾病（LRTD） ) 在 60 歲及以上的個體中.